Overview

This trial is active, not recruiting.

Condition over active bladder
Treatment bluewind medical system
Phase phase 1
Sponsor BlueWind Medical
Start date February 2015
End date July 2016
Trial size 40 participants
Trial identifier NCT02299544, CP-03-001

Summary

BlueWind system safety and performance in treatment of patients diagnosed with overactive bladder (OAB)

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Endpoint classification safety study
Intervention model single group assignment
Masking open label
Primary purpose treatment
Arm
(Experimental)
Patients with overactive bladder (OAB) with or without urge incontinence. Two patient populations will be enrolled in the study: Patients with no previous treatment with percutaneous tibial nerve stimulation (PTNS) [de novo patient group] and Patients with a documented success on PTNS therapy [prior-PTNS group]. Documented success on PTNS is defined by a ≥50% reduction in urinary frequency, and/or ≥50% fewer incontinence episodes, or a return to normal voiding frequency [<8 voids/day], based on retrospective diary review. All patients will be treated with BlueWind Medical System.
bluewind medical system
The BlueWind Medical System is intended for the treatment of patients with overactive bladder (OAB) including urinary urgency frequency and urge incontinence.

Primary Outcomes

Measure
incidence of serious adverse events
time frame: up to 6 months follow up

Eligibility Criteria

Male or female participants from 18 years up to 80 years old.

Inclusion Criteria: - Signed written informed consent. - Male or female aged 18 - 80. - Patient agrees to attend all follow-up evaluations and is willing to completely and accurately fill out voiding diaries and questionnaires, and is willing to complete required exams and tests. - Patients with overactive bladder symptoms: - Urinary frequency greater than 8 times/24 hours AND/OR Urinary urgency leaks of at least 2 leaks on 3 day voiding diary - Patient who has failed conservative treatment after at least 6 months of treatment - Patients with normally functioning upper urinary tract. - Patients with no clinical evidence of a neurological S2-S4 motor sensory deficit. - Prior PTNS Group: Patients who have had successful PTNS treatment (successful treatment is defined as ≥50% reduction in urinary frequency, and/or ≥50% fewer incontinence episodes, or a return to normal voiding frequency [<8 voids/day], based on retrospective diary review). - De novo Patient Group: Patient who passes the BlueWind compatibility test. Exclusion Criteria: - Any metal implant in the area of BlueWind Medical implantation site. - Patients who have not had stable OAB medications for at least 30 days. - Patients who have received botulinum toxin injections within the past 6 months. - Previous urinary incontinence surgery or implantation of artificial graft material within the last 6 months. - Any spinal or genitourinary surgery within the last 6 months. Pelvic pain disorders - Obvious clinically demonstrated genuine stress incontinence. - Any neurological disease or disorder including neuropathy or injury resulting in neuropathy. - Current urinary tract infection, presence of urinary stone and/or urinary tract malignancy (i.e. tumor, vesicourethral reflux, etc.) - Pelvic radiotherapy and chemotherapy. - Severe uncontrolled diabetes. - Patients anticipating magnetic resonance imaging (MRI) exams. - Presence of cystocele, enterocele or rectocele of grade 3 or 4. - Prior PTNS Group: Patients who are receiving concomitant nerve stimulation therapies for OAB treatment, except for PTNS maintenance therapy. - De novo Patient Group: Patients who have received or are receiving nerve stimulation therapies for OAB treatment, including PTNS.

Additional Information

Official title Safety and Performance of the BlueWind System for the Treatment of Patients With Overactive Bladder (OAB)
Principal investigator John Heesakkers, MD
Description BlueWind Medical system safety and performance in treatment of patients diagnosed with overactive bladder (OAB)
Trial information was received from ClinicalTrials.gov and was last updated in October 2015.
Information provided to ClinicalTrials.gov by Rainbow Medical.